Poster
30
(#30) Persistence of Cariprazine Vs Lumateperone Among Patients With Bipolar I Depression: A Real-World Claims-Based Study
Psych Congress 2025
Abstract: Background: There is limited evidence on comparative persistence among atypical antipsychotics (AAs) approved for bipolar I (BP-I) depression. This study compared real-world treatment persistence with cariprazine versus lumateperone among patients with BP-I depression.
Methods: Claims data from the Komodo Research Database (12/20/2020-11/30/2024) were used to identify commercially insured patients with BP-I depression who initiated cariprazine or lumateperone. Patients had ≥2 pharmacy claims for cariprazine or lumateperone and ≥3 months of follow-up. Baseline characteristics of AA cohorts were balanced using the inverse probability of treatment weighting approach based on the propensity score. Kaplan-Meier analyses assessed persistence, which was defined as time on treatment without discontinuation (>60-day gap between end of supply and next fill or end of follow-up period) in weighted cariprazine and lumateperone cohorts; Cox proportional hazards models compared persistence using hazard ratios (HRs).
Results: The analysis included 2330 patients prescribed cariprazine and 571 prescribed lumateperone. The proportion of patients persistent on cariprazine and lumateperone was 62.9% and 56.9%, respectively, at 6 months and 45.4% and 39.4%, respectively, at 12 months. The median duration of persistence for cariprazine and lumateperone was 300 and 244 days, respectively. Compared with patients taking lumateperone, patients taking cariprazine were 23% more likely to be persistent at 6 months (HR [95% CI]=1.23 [1.06, 1.42], P=.005) and 19% more likely to be persistent at 12 months (1.19 [1.05, 1.35], P=.007).
Conclusions: This real-world study found that patients with BP-I depression had significantly greater persistence on cariprazine versus lumateperone.
Short Description: This claims-based study compared treatment persistence of cariprazine and lumateperone among commercially insured patients with bipolar I depression. Cariprazine was associated with significantly higher persistence at 6 and 12 months versus lumateperone after initiation.
Name of Sponsoring Organization(s): AbbVie
Methods: Claims data from the Komodo Research Database (12/20/2020-11/30/2024) were used to identify commercially insured patients with BP-I depression who initiated cariprazine or lumateperone. Patients had ≥2 pharmacy claims for cariprazine or lumateperone and ≥3 months of follow-up. Baseline characteristics of AA cohorts were balanced using the inverse probability of treatment weighting approach based on the propensity score. Kaplan-Meier analyses assessed persistence, which was defined as time on treatment without discontinuation (>60-day gap between end of supply and next fill or end of follow-up period) in weighted cariprazine and lumateperone cohorts; Cox proportional hazards models compared persistence using hazard ratios (HRs).
Results: The analysis included 2330 patients prescribed cariprazine and 571 prescribed lumateperone. The proportion of patients persistent on cariprazine and lumateperone was 62.9% and 56.9%, respectively, at 6 months and 45.4% and 39.4%, respectively, at 12 months. The median duration of persistence for cariprazine and lumateperone was 300 and 244 days, respectively. Compared with patients taking lumateperone, patients taking cariprazine were 23% more likely to be persistent at 6 months (HR [95% CI]=1.23 [1.06, 1.42], P=.005) and 19% more likely to be persistent at 12 months (1.19 [1.05, 1.35], P=.007).
Conclusions: This real-world study found that patients with BP-I depression had significantly greater persistence on cariprazine versus lumateperone.
Short Description: This claims-based study compared treatment persistence of cariprazine and lumateperone among commercially insured patients with bipolar I depression. Cariprazine was associated with significantly higher persistence at 6 and 12 months versus lumateperone after initiation.
Name of Sponsoring Organization(s): AbbVie
